AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

Sylvie M. Guichard(Novo Nordisk (United Kingdom)), Sabina Cosulich(AstraZeneca (Singapore))

Molecular Cancer Therapeutics

September 11, 2015

10.1158/1535-7163.mct-15-0365

Cited by 125

Related Papers

Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor

|Nature|2016|483

The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia

|Leukemia|2011|161

Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase

|Breast Cancer Research|2014|70

FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer

|Targeted Oncology|2023|30